Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > February 2013 - Volume 20 - Issue 2 > Sexual dysfunction in women on adjuvant endocrine therapy af...
Menopause:
doi: 10.1097/GME.0b013e31826560da
Original Articles

Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer

Baumgart, Juliane MD, PhD1,2; Nilsson, Kerstin MD, PhD1,3; Evers, Anneli Stavreus PhD4; Kallak, Theodora Kunovac MSc4; Poromaa, Inger Sundström MD, PhD4

Editorial
Collapse Box

Abstract

Objective: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.

Methods: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.

Results: In all, 42.4% of aromatase inhibitor–treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor–treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.

Conclusions: Our findings suggest that sexual dysfunction in aromatase inhibitor–treated women is a greatly underestimated problem.

©2013The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.